6月2日 - ** NRx Pharmaceuticals股价 NRXP.O 在盘后交易中下跌22%，至3.60美元，该公司正寻求股权融资
** 专注于抑郁症、慢性疼痛及创伤后应激障碍（PTSD）治疗的生物制药公司宣布发行 (link) 股票；交易规模未披露
** 该公司计划将募集资金净额用于营运资金及支持业务增长
** BTIG担任主承销商，Lucid Capital Markets参与承销
** 总部位于特拉华州的NRXP流通股约3620万股，市值约1.7亿美元
** 该股周二收盘持平于4.62美元，年内累计涨幅约70%
** 据LSEG数据显示，覆盖该股的5位分析师均给予“强烈买入”或“买入”评级；目标价中位数为45美元
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.